BACKGROUND: Structural valve deterioration (SVD) is a major obstacle to lifetime durability for bioprosthetic heart valves. A bio-prosthetic valve created with RESILIA™ tissue was designed to produce long-term resistance to SVD. AIM: The objective of this study was to evaluate the safety and performance of this new class of RESILIA™ tissue aortic bio-prosthesis. METHODS: A nonrandomised, prospective, multi-centre, single-arm, observational study was performed in 133 patients who underwent surgical aortic valve replacement between July 2011 and February 2013. Patients were assessed at 3-6 months and one year for haemodynamic performance, clinical outcomes, and functional improvement. RESULTS: The mean age was 65.3 ± 13.5 years, with 34 (25.6%) of patients < 60 years of age. Early (≤ 30 day) and late (> 30 day) all-cause mortality rates were 2.3% (n = 3) and 4.5% (n = 6), respectively. Early events included thromboembolism in three (2.3%) patients and major bleeding events requiring transfusion in six (4.5%) patients. Late events included one endocarditis leading to explant. Mean gradients were reduced across all valve sizes and were maintained at one year of follow-up. The mean effective orifice area and effective orifice area index increased across all valve sizes postoperatively and were maintained at one year. The rates of paravalvular leak (> 2+) at 3-6 months and one-year follow-up were 0.7% and 0.7%, respectively. CONCLUSIONS: The new generation RESILIA™ tissue aortic valve bioprosthesis demonstrated excellent haemodynamic per-formance and safety outcomes at one year of follow-up. Longer follow-up of these patients will provide further insight on long-term durability.
BACKGROUND:Structural valve deterioration (SVD) is a major obstacle to lifetime durability for bioprosthetic heart valves. A bio-prosthetic valve created with RESILIA™ tissue was designed to produce long-term resistance to SVD. AIM: The objective of this study was to evaluate the safety and performance of this new class of RESILIA™ tissue aortic bio-prosthesis. METHODS: A nonrandomised, prospective, multi-centre, single-arm, observational study was performed in 133 patients who underwent surgical aortic valve replacement between July 2011 and February 2013. Patients were assessed at 3-6 months and one year for haemodynamic performance, clinical outcomes, and functional improvement. RESULTS: The mean age was 65.3 ± 13.5 years, with 34 (25.6%) of patients < 60 years of age. Early (≤ 30 day) and late (> 30 day) all-cause mortality rates were 2.3% (n = 3) and 4.5% (n = 6), respectively. Early events included thromboembolism in three (2.3%) patients and major bleeding events requiring transfusion in six (4.5%) patients. Late events included one endocarditis leading to explant. Mean gradients were reduced across all valve sizes and were maintained at one year of follow-up. The mean effective orifice area and effective orifice area index increased across all valve sizes postoperatively and were maintained at one year. The rates of paravalvular leak (> 2+) at 3-6 months and one-year follow-up were 0.7% and 0.7%, respectively. CONCLUSIONS: The new generation RESILIA™ tissue aortic valve bioprosthesis demonstrated excellent haemodynamic per-formance and safety outcomes at one year of follow-up. Longer follow-up of these patients will provide further insight on long-term durability.
Entities:
Keywords:
RESILIA; aortic valve replacement; new technology
Authors: Paolo Nardi; Calogera Pisano; Fabio Bertoldo; Sara Rita Vacirca; Monica Greci; Carlo Bassano; Antonio Scafuri; Antonio Pellegrino; Giovanni Ruvolo Journal: J Thorac Dis Date: 2019-04 Impact factor: 2.895
Authors: Krzysztof Bartus; Radoslaw Litwinowicz; Agata Bilewska; Maciej Stapor; Maciej Bochenek; Jacek Rozanski; Jerzy Sadowski; Grzegorz Filip; Boguslaw Kapelak; Mariusz Kusmierczyk Journal: J Thorac Dis Date: 2019-07 Impact factor: 2.895
Authors: Chi Chi Do-Nguyen; Maxwell F Kilcoyne; Randy M Stevens; James Starc; Nandini Madan; Vicki Mahan; Cesar Igor Mesia; Achintya Moulick Journal: Clin Case Rep Date: 2020-03-31
Authors: Krzysztof Bartus; Radosław Litwinowicz; Jerzy Sadowski; Grzegorz Filip; Mariusz Kowalewski; Piotr Suwalski; Piotr Mazur; Anna Kędziora; Marek Jasiński; Marek Deja; Mariusz Kuśmierczyk; Pawel Czub; Michal Zembala; Marek Jemielity; Rafał Pawlaczyk; Zdzisław Tobota; Bohdan Maruszewski; Boguslaw Kapelak Journal: J Thorac Dis Date: 2020-10 Impact factor: 3.005
Authors: Krzysztof Bartus; Jerzy Sadowski; Radoslaw Litwinowicz; Grzegorz Filip; Marek Jasinski; Marek Deja; Mariusz Kusmierczyk; Szymon Pawlak; Marek Jemielity; Dariusz Jagielak; Piotr Hendzel; Piotr Suwalski; Zdzisław Tobota; Bohdan Maruszewski; Boguslaw Kapelak Journal: J Thorac Dis Date: 2019-06 Impact factor: 2.895
Authors: Grzegorz Filip; Magdalena A Bryndza; Janusz Konstanty-Kalandyk; Jacek Piatek; Piotr Wegrzyn; Piotr Ceranowicz; Maciej Brzezinski; Dhanunjaya Lakkireddy; Boguslaw Kapelak; Krzysztof Bartuś Journal: Kardiochir Torakochirurgia Pol Date: 2018-12-31